Xanthine derivatives
AssigneeKyowa Hakko Kogyo Co., Ltd.
InventorsFumio Suzuki, Nobuaki Koike, Junichi Shimada, Joji Nakamura, Shizuo Shiozaki, Shigeto Kitamura, Shunji Ichikawa, Hiroshi Kase, Hiromi Nonaka
Life of this patent
Estimating the term…
Loading patent…
AssigneeKyowa Hakko Kogyo Co., Ltd.
InventorsFumio Suzuki, Nobuaki Koike, Junichi Shimada, Joji Nakamura, Shizuo Shiozaki, Shigeto Kitamura, Shunji Ichikawa, Hiroshi Kase, Hiromi Nonaka
Estimating the term…
The present invention relates to novel xanthine derivatives and pharmaceutically acceptable salts thereof, represented by Formula (I): ##STR1## wherein R.sup.1, R.sup.2, and R.sup.3 independently represent hydrogen, lower alkyl, lower alkenyl, or lower alkynyl, R.sup.4 represents lower alkyl, or substituted or unsubstituted aryl, R.sup.5 and R.sup.6 independently represent hydrogen, lower alkyl, and lower alkoxy, or R.sup.5 and R.sup.6 are combined together to represent --O--(CH.sub.2)p--O-- (p is an integer of 1 to 3), n represents 0, 1, or 2, and m represents 1 or 2. The compounds of the present invention have an adenosine A.sub.2 receptor antagonistic activity, and are useful for the treatment or prevention of various kinds of diseases caused by hyperergasia of adenosine A.sub.2 receptors (for example, Parkinson's disease, senile dementia, depression, asthma, and osteoporosis).
A xanthine derivative represented by Formula (I) or its pharmaceutically acceptable salt:
Dependencies are inferred from the claim text.